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http://dx.doi.org/10.1016/j.ccr.2012.06.029SUMMARYHepatocyte growth factor (HGF) and vascular endothelial cell growth factor (VEGF) regulate normal develop-
ment and homeostasis and drive disease progression in many forms of cancer. Both proteins signal by
binding to receptor tyrosine kinases and heparan sulfate (HS) proteoglycans on target cell surfaces. Basic
residues comprising the primary HS binding sites on HGF and VEGF provide similar surface charge distribu-
tionswithout underlying structural similarity. Combining three acidic amino acid substitutions in these sites in
the HGF isoform NK1 or the VEGF isoform VEGF165 transformed each into potent, selective competitive
antagonists of their respective normal and oncogenic signaling pathways. Our findings illustrate the impor-
tance of HS in growth factor driven cancer progression and reveal an efficient strategy for therapeutic antag-
onist development.INTRODUCTION
Heparan sulfate (HS) glycosaminoglycans (GAGs) are complex
polysaccharides present on cell surfaces and in extracellular
matrices that modulate cell growth and differentiation, and in
turn, embryogenesis, angiogenesis, and homeostasis (reviewed
in Sarrazin et al., 2011). Their extended conformation and high
negative charge enhance tissue integrity, and their inherentSignificance
Heparan sulfate (HS) proteoglycans are widely expressed, stru
protein-protein interactions. Hepatocyte growth factor (HGF)
development and homeostasis and drive tumorigenesis, tum
We show that targeted disruption of specific HS binding resid
of these pathways. The similar roles of HS in enabling receptor
suggest that this occurs through convergent evolutionary adap
an efficient strategy for the development of antagonists of thes
spread involvement in cancer.
250 Cancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc.complexity provides selective yet substantial protein binding
capacity (Sarrazin et al., 2011). Protein binding enables the
formation of growth factor gradients during development and
reservoirs for factors needed rapidly for tissue repair and regen-
eration in adults (Sarrazin et al., 2011). Cell surface HSproteogly-
cans form ternary complexes with growth factors and their
receptors, enhancing complex stability and signaling (Sarrazin
et al., 2011; Mohammadi et al., 2005).cturally diverse biopolymers that modulate many important
and vascular endothelial cell growth factor (VEGF) regulate
or angiogenesis, and metastasis in many forms of cancer.
ues in HGF and VEGF yields selective competitive inhibitors
activation, in the absence of underlying structural similarity,
tation to the common binding partner, HS. Our results reveal
e and potentially other HS binding growth factors with wide-
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Inhibition of Oncogenic HGF and VEGF SignalingHepatocyte growth factor (HGF) and vascular endothelial cell
growth factor (VEGF) bind HS and regulate development and
homeostasis (Ferrara, 2004; Matsumoto and Nakamura, 1996;
Michalopoulos, 2007) and drive tumor growth, angiogenesis,
and metastasis in many cancers (Boccaccio and Comoglio,
2006; Ferrara, 2004; Peschard and Park, 2007). HGF induces
growth, motility, and morphogenesis in a variety of cell types
via the Met receptor kinase (Peschard and Park, 2007). VEGF-
A is an essential regulator of angiogenesis (Ferrara, 2004) that
stimulates growth, motility, and tubulogenesis in vascular endo-
thelial cells through the receptor kinases VEGFR1 (Flt-1) and
VEGFR2 (Flk-1, kinase insert domain receptor [KDR]) and the
coreceptors neuropilin-1 (NRP1) and NRP2 (Ferrara, 2004;
Favier et al., 2006; Gluzman-Poltorak et al., 2000).
The HGF and VEGF genes encode multiple isoforms. Mature
HGF is a plasminogen-like protein that comprises an amino-
terminal heavy chain with four kringle motifs and a carboxyl-
terminal light chain with a serine protease-like domain (Matsu-
moto and Nakamura, 1996). Two truncated HGF isoforms also
exist: the shorter of these retains HGF activities at modestly
reduced potency and consists of the amino-terminal (N) domain
linked to kringle 1 (NK1) (Stahl et al., 1997). Within NK1,
N contains the HS binding site (Hartmann et al., 1998; Kinosaki
et al., 1998; Lietha et al., 2001; Mizuno et al., 1994; Okigaki
et al., 1992; Sakata et al., 1997; Zhou et al., 1998, 1999), and
K1 contains the primary Met binding site (Lokker et al., 1994;
Rubin et al., 2001).
VEGF-A pre-mRNA splicing yields multiple VEGF-A isoforms,
primarily VEGF121, VEGF165, and VEGF189 (Ferrara, 2004).
These contain the same binding sites for VEGFR1 and R2, but
differ in HS binding capacity by the presence or absence of
domains encoded by exon 6 and exon 7 (Robinson and Stringer,
2001). Exon 7- and exon 8-encoded domains enable VEGF-A
to bind NRP1 (Appleton et al., 2007; Ferrara, 2004). Unlike
VEGF165 and VEGF189, VEGF121 lacks HS binding and is freely
diffusible (Carmeliet et al., 1999). HS binding has significant
impact on VEGF-A biology: mice engineered to express only
VEGF121 display defective microvessel branching and lethality
shortly after birth (Carmeliet et al., 1999). Yet, even VEGF121
signaling is HS dependent: similar to fibroblast growth factors
(FGFs) and HGF, HS facilitates VEGF signaling through interac-
tions with both ligand and receptor (Lyon et al., 2002; Moham-
madi et al., 2005; Rubin et al., 2001; Sarrazin et al., 2011).
Thus, complete disruption of HS function in VEGF signaling is
likely to mimic the embryonic lethality associated with homozy-
gous deletions of VEGF, VEGFR, or the HS proteoglycan perle-
can (Ferrara, 2004; Sarrazin et al., 2011).
Basic residues critical for HS binding have been identified in
HGF and VEGF165 (Chirgadze et al., 1999; Krilleke et al., 2007;
Lietha et al., 2001; Ultsch et al., 1998; Zhou et al., 1998, 1999).
Combined alanine substitutions in the VEGF165 HS binding site
resulted in reduced binding to NRP1 and VEGFR1 (Krilleke
et al., 2007). Alanine substitutions in the HS binding site of HGF
(Kinosaki et al., 1998) or NK1 (Lokker et al., 1994; Sakata et al.,
1997) resulted in modest functional change. Negative charge
substitutions that more effectively disrupt HS binding distin-
guished functionally relevant sites in HGF over earlier studies
(Hartmann et al., 1998), so this strategywas used to further define
the importance of HS binding for Met and VEGFR signaling.RESULTS
Substituted NK1 Forms Have Normal Folding and Met
Binding but Diminished HS Binding and Signaling
The highly conservedN domain residues K60, K62, andR73 form
the primary HS binding site in HGF and R76, K78, R35, and R36
contribute secondarily (Chirgadze et al., 1999; Lietha et al., 2001;
Ultsch et al., 1998; Zhou et al., 1998, 1999; Table S1 available on-
line). Within the HS binding domain of VEGF165, residues R123,
R124, and R159 are also highly conserved and critical for heparin
binding (Krilleke et al., 2007; Table S1). Although HGF and VEGF
have neither significant sequence identity nor similarity in
peptide backbone fold, the tripartite HS binding sites in both
show a similar distribution of positive surface charge (Figure S1).
Expression plasmids were constructed that substituted acidic
for basic residues to disrupt the surface charge distribution on
NK1: R73E (designated 1S), K60E/K62E (2S), and K60E/K62E/
R73E (3S). Substituted and wild-type (WT) NK1 proteins were
expressed and purified to >99% homogeneity (Figure S2). To
confirm proper folding of the substituted proteins, their struc-
tures were compared with WT by nuclear magnetic resonance
(NMR) spectrometry (Figure 1). Minor shifts in the pattern of
two-dimensional 1H-15N correlation spectra for substituted
proteins overlaid on NK1 WT spectra clustered near the substi-
tution sites, indicating minimal perturbation of the three-dimen-
sional structure in the substituted proteins.
Competitive binding experiments using ruthenium (Ru) tagged
NK1 WT protein bound to immobilized heparin with displace-
ment by untagged WT or 3S proteins showed that binding by
the 3S form was 10-fold lower than WT (p < 0.001; Figure 2A).
The IC50 for WT was consistent with prior estimates of NK1-
and NK2-heparin binding (Hartmann et al., 1998; Rubin et al.,
2001). Elution of the substituted proteins from a heparin affinity
column by a NaCl gradient also showed reduced binding relative
to WT, most severely in NK1 3S, reinforcing prior evidence that
residues 60, 62, and 73 are sites of HS interaction (Table S2).
Saturation binding of tagged NK1WT and 3S proteins to aMet
ectodomain-Ig fusion protein in the presence of HS oligomer
(4.2 kDa) or HS tetramer (1.2 kDa) produced similar results
(Figures 2B and 2C), indicating that Met binding was unchanged,
as anticipated. Competitive displacement of HGF by NK1 WT or
3S also yielded IC50 values of 1 nM (data not shown). Satura-
tion binding of tagged NK1 3S to the Met-Ig protein was unaf-
fected by the absence of HS (Figure 2B, triangles); in contrast,
NK1WT binding to Met-Ig in the absence of HS was significantly
compromised (Figure 2C, triangles). Heparin (18 kDa)
substituted effectively for either HS form in enhancing NK1
WT-Met binding (data not shown). Together, these results
suggest that masking the positive surface charge of residues
60, 62, and 73 with bound HS in NK1 WT improves its Met
binding affinity and that this was achieved artificially in NK1 3S
by the negative charge substitutions.
Disruption of the primary HS binding site in NK1 diminished its
biological activity in cultured cells. Ligand-induced Met auto-
phosphorylation in human epithelial (184B5) cells was lower in
cells treated with NK1 1S or 2S proteins relative to NK1 WT or
HGF (data not shown) and undetectable in cells treated with
NK1 3S protein (Figure 2D). Ligand-stimulated cell migration
(Figure 2E) and mitogenesis (Figure 2F) revealed similar patternsCancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc. 251
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Figure 1. NMR Analysis of NK1 Proteins
1H-15N correlation spectra for substituted NK1 proteins (red) superimposed on NK1 WT spectra (blue).
(A) NK1 3S.
(B) NK1 2S.
(C) NK1 1S.
Spectra that are shifted in the substituted proteins are labeled in (A), (B), and (C).
See also Figure S1 and Table S1.
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Figure 2. NK1 3S Has Reduced HS Binding and Normal Met Binding
and Fails to Activate Met Signaling
(A–C) Competitive displacement of Ru tagged NK1 WT from immobilized
heparin by untagged NK1 WT (triangles) or 3S (circles) (A). Saturation binding
of Ru tagged NK1 3S (B) or NK1 WT (C) to Met ectodomain-Ig in the absence
(triangles) or presence of HS oligomer (circles) or HS tetramer (squares). For
(A), (B), and (C) values are mean signal intensity (SI) ± SD (n = 3).
(D) MeanMet activation (phospho-Met [pM] per total protein [ug] ± SD; n = 3) in
184B5 cells left untreated (‘‘C’’) or treated with HGF (1 nM), NK1 WT (5 nM), or
NK1 3S (5 nM) for 20 min. Met content was equivalent in all samples. Asterisks
indicate significant differences from control (p < 0.01).
(E) Mean number of 184B5 cells (± SD; n = 3) migrating in response to treat-
ment with NK1 WT or substituted NK1 proteins (7 nM each) in 24 hr. Asterisks
indicate significant differences from control (p < 0.01).
(F) Mean DNA synthesis values ([3H]thymidine incorporation cpm±SD; n = 3) in
184B5 cells after 16 hr treatment with NK1 WT or substituted proteins at the
indicated concentrations: WT (circles); 1S (triangles); 2S (squares); and 3S
(inverted triangles).
See also Figure S2 and Table S2.
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Figure 3. Long HS Polymers Promote NK1 Clustering, Met Activa-
tion, and Signaling
(A and B) Purified NK1WT (A), or NK1 3S proteins were incubated alone or with
BS3 crosslinker in the absence or presence of heparin (Hep), HS oligomers
(HSoligo), or HS tetramers (HStetra) before analysis by SDS-PAGE and immu-
noblotting (B). Arrows between (A) and (B) indicate the masses of NK1
monomer (24 kDa) and NK1 multimers.
(C–F) The activation states of Met (mean phospho-Met/Met/total protein ± SD;
n = 3; C), Akt (D), GSK3b (E), or p70S6K (F) in serum-deprived CHO 745 cells
that were untreated (unfilled bars, ‘‘C’’) or treated with NK1 WT (200 pM; gray
bars) in the absence () or presence of HS tetramer (HStetra) or heparin (Hep).
Values for (D–F) are mean signal intensity units (± SD; n = 3). Asterisks indicate
significant differences from control (p < 0.01).
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Inhibition of Oncogenic HGF and VEGF Signalingof functional compromise among the substituted NK1 forms: the
1S and 2S proteins showed reduced activity (p < 0.01), and the
3S protein was inactive.
NK1-HS Binding Enables NK1 Clustering, Met
Activation, and Signaling
Loss of signaling by NK1 3S despite native Met binding
implied that HS binding enabled a critical step in Met activation.
HGF and NK1 are monomers in solution, and it is thought that
long HS chains capable of binding several HGF molecules
promote and stabilize ligand clustering, and in turn, the clus-
tering of ligand-receptor complexes (Chirgadze et al., 1999;
Gherardi et al., 2006; Lietha et al., 2001; Hartmann et al., 1998;
Rubin et al., 2001; Schwall et al., 1996; Tolbert et al., 2007;
Zhou et al., 1999). Consistent with this concept, 18 kDa heparin
or 4.2 kDa HS oligomer supported NK1 WT multimer formationdetected after covalent affinity crosslinking, SDS-PAGE, and
immunoblotting (Figure 3A, lanes 4 and 8). HS tetramers
(1.2 kDa) unable to bind more than one NK1 molecule (Lyon
et al., 2002) did not support NK1 WT multimer formation (Fig-
ure 3A, lane 6). The masses of the observed NK1 WT oligomers
corresponded to dimers, trimers, and tetramers of NK1 (Fig-
ure 3A). As anticipated, HS-NK1 3S complexes were not de-
tected (Figure 3B).
The impact ofHSchain length onNK1-drivenMet signalingwas
investigated using Chinese hamster ovary (CHO) 745 cells, which
lack HS (Sarrazin et al., 2011). NK1-Met binding and NK1 clus-
tering on cell surfaces were found to be HS dependent in CHO
745 (Sakata et al., 1997). Consistent with this, and other studies
(Lyon et al., 2002, 2004),Met TK activation (Figure 3C) and conse-
quent activation of Akt (Figure 3D), glycogen synthase kinase 3bCancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc. 253
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Inhibition of Oncogenic HGF and VEGF Signaling(GSK3b) (Figure3E), andp70S6K (Figure3F) byNK1WT in this cell
line was enhanced by added 18 kDa heparin. In contrast, added
1.2 kDa HS tetramer did not enhance NK1 WT signaling (Figures
3C–3F), despite enabling high affinity NK1-Met binding (Fig-
ure 2C). These observations suggest that the clustering of NK1
afforded by longer HS chains stabilized NK1-Met complex
oligomerization, and, in turn, Met signaling. The relative order in
which ligand-HS, ligand-Met, and Met-HS binding events occur
is unknown and may be dictated by the relative abundance of
HS and Met on target cells. We note that HS tetramer enabled
modest mitogen-activated protein kinase (MAPK) activation by
HGF (Lyon et al., 2002); as suggested by Stamos et al. (2004),
the HGF light chain may contribute to HGF/Met/HS complex
dimerization through homotypic interactions between light-chain
protomers.
NK1 3S Is a Potent, Selective Competitive Antagonist
of NK1 and HGF Signaling
The properties of the NK1 3S protein suggested that it might
competitively antagonize HGF activity. Indeed, addition of 3S
protein to HGF- and NK1-treated cells resulted in dose-depen-
dent inhibition Met kinase activation in normal cells (Figure 4A,
circles and squares). The IC50 values for 3S inhibition of Met acti-
vation by HGF and NK1WT were 6 nM, 10-fold more potent than
the Met antagonist PHA665752 (IC50 = 60 nM; Figure 4A, trian-
gles). NK1 WT-induced DNA synthesis was also inhibited by
3S protein, with >90% inhibition at 10-fold molar excess 3S
over WT NK1 (Figure 4B, circles).
CD44 variants containing exon 6 (v6) are implicated in onco-
genic Met signaling (Orian-Rousseau et al., 2002), and those
containing exon 3 are often modified with HS and promote
HGF-Met interaction (van der Voort et al., 1999; Wielenga
et al., 2000). CD44 variants containing both exons occur
frequently in colon and prostate cancer-derived cell lines, such
as HT29 and PC3M, respectively, and in colon and prostate
carcinomas where their expression correlates with poor prog-
nosis (van der Voort et al., 1999; Wielenga et al., 2000). We
analyzed Met-CD44 association to determine if NK1 3S-Met
binding affected this process. Met-CD44 association was
induced by HGF or NK1 WT in HT29 cells (Figure 4C, lanes 2
and 3) and by HGF in PC3M cells (Figure 4D, lane 2), but not
by NK1 3S in either cell line (Figure 4C, lane 4; Figure 4D, lane
6). In PC3M,NK1 3S antagonized HGF-inducedMet-CD44 asso-
ciation in a dose-dependent manner, while PHA665752 was less
effective (Figure 4D, lanes 2–5 versus lanes 7–9).
Oncogenic autocrine HGF/Met signaling occurs frequently in
glioblastoma (Boccaccio and Comoglio, 2006) and drives tumor-
igenicity in the glioblastoma-derived cell line U87 MG. Stable
expression of NK1 3S in U87 MG cells significantly reduced
proliferation relative to cells expressing NK1WT or empty vector
(Figure 4E). HGF and Met protein levels were comparable in the
three cell lines, as were the levels of NK1 WT and 3S proteins
(Figures S3A–S3E). U87 MG cells do not express NK1 mRNA,
thus reduced growth resulted from NK1 3S inhibition of endoge-
nous HGF signaling.
We extended our initial analysis of NK1 3S inhibition of cell
motility (Figure 2E) using the Madin-Darby Canine Kidney
(MDCK) cell scatter assay (Figure 4F). NK1 3S had no intrinsic
scatter activity (Figure 4F, third panel from left); inhibition of254 Cancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc.HGF-induced scatter was dose-dependent and complete at
50-fold molar excess (Figure 4F, right three panels).
NK1 3S also blocked anchorage independent growth by U87
MG cells (Figure 4G). U87 MG cells grow robustly in soft agar,
(Figure 4G, left panel), but cells expressing NK1 3S failed to
form colonies under identical conditions (Figure 4G, second
panel from left). Colony formation was also suppressed by add-
ing purified NK1 3S protein to the medium, with 50% inhibition
by 70 nM 3S and complete blockade by 300 nM relative to
controls (Figure 4G, third and fourth panels from left); similar
levels of inhibition were observed for PHA665752 (Figure 4G,
right two panels).
The Met selectivity of NK1 3S antagonism was confirmed
using the endothelial hybrid cell line EA.hy 926, which expresses
both Met and KDR. Cells were stimulated with either NK1 WT or
VEGF165 in the presence or absence of 10-fold molar excess
NK1 3S, and the activation levels of Met, Akt, GSK3b, and
p70S6K were measured by 2-site immunoassays (Figures
S3F–S3I). NK1 3S did not activate Met or downstream effectors
(Figures S3F–S3I, left versus right white bars). NK1WT activated
Met, Akt, and its targets relative to control cells (Figures S3F–S3I,
left white versus left gray bars), and this signaling cascade was
completely suppressed by added excess NK1 3S (Figures
S3F–S3I, right gray bars). In contrast, although VEGF165 fully
activated the Akt pathway, excess NK1 3S had no effect (Figures
S3F–S3I, left versus right black bars). Similar results were
observed for VEGF165 activation of the MAPK pathway kinases
pERK-1/2, pJNK, and pp38MAPK in the presence or absence of
NK1 3S (data not shown).
NK1 3S Inhibits HGF Signaling, Tumor Growth,
and Metastasis In Vivo
NK1 3S antitumor activity was first assessed by xenograft
studies of transfected U87 MG cell lines in severe combined
immunodeficiency (SCID)/beige mice (Figure 5A). Animals
receiving theU87MG/NK1WTcell line started to develop tumors
in 5 days (Figure 5A, squares), and tumor growth rate was twice
that of the control cell line (Figure 5A, circles), consistent with the
additive effects of ectopic NK1 WT and endogenous HGF. In
contrast, tumor growth in animals receiving U87 MG/NK1 3S
cells was not measurable before 50 days (Figure 5A, triangles).
Like U87 MG, the human leiomyosarcoma-derived cell line
SK-LMS-1 has autocrine HGF/Met activation. SK-LMS-1 cells
were transfected with plasmids for NK1 WT, NK1 3S, or with
empty vector, and cell clones were selected for equivalent
expression of endogenous HGF and Met and ectopic NK1 WT
and NK1 3S proteins (Figures S3A–S3E). Again, NK1WT expres-
sion accelerated tumor growth (Figure 5B, squares), whereas
NK1 3S expression reduced mean tumor volume by 75% after
68 days relative to controls (Figure 5B, triangles versus circles;
p < 0.001). Tumors resected from these mice displayed equiva-
lent Met content among the three groups (not shown); Met
activationwas highest in NK1WT transfectant tumors (Figure 5C,
black bar), significantly lower in tumors from controls (Figure 5C,
gray bar), and lowest in tumors from the NK1 3S implanted group
(Figure 5C, white bar; p < 0.001).
HGF/Met signaling is a critical contributor to tumor metas-
tasis (Boccaccio and Comoglio, 2006). NK1 3S was tested in
the B16 murine melanoma model of induced metastasis, where
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Figure 4. NK1 3S Is a Potent Antagonist of NK1 and HGF Signaling
(A) Mean Met activation level (% maximum ± SD; n = 3) in 184B5 cells treated with HGF (1 nM; circles) or NK1 WT (5 nM; squares) and with increasing
concentrations of NK1 3S. HGF-stimulated cells were treated with PHA665752 (triangles) over the same dose range in parallel.
(B) Mean DNA synthesis level (% maximum [3H]thymidine incorporation ± SD; n = 3) in 184B5 cells treated with NK1 WT and NK1 3S (circles), or in cells treated
with NK1 3S alone (squares) at the indicated doses.
(C) Met-CD44 association in HT29 cells incubated with NK1 3S (5 nM), NK1 WT (5 nM), or HGF (1 nM) as indicated, in the presence of DTSSP prior to immu-
noprecipitation with anti-CD44, SDS-PAGE, and immunoblotting with anti-Met (upper panel) or anti-CD44 (lower panel).
(D) Met-CD44 association in PC3M cells treated with HGF (1 nM) and DTSSP in the absence or presence of NK1 3S or PHA665752 (PHA) at the indicated
concentrations (nM) prior to immunoprecipitation with anti-CD44, SDS-PAGE, and immunoblotting with anti-Met (upper panel) or anti-CD44 (lower panel).
(E) Proliferation of U87 MG cells (mean cell number ± SD; n = 3) expressing NK1 WT (squares), NK1 3S (triangles), or empty vector (circles).
(F) NK1 3S antagonism of HGF-stimulated MDCK cell scatter. Unstimulated control cells or cells treated with HGF or NK1 3S at the indicated concentrations (left
three panels). HGF-stimulated cells treated with NK1 3S at the indicated concentrations (right three panels).
(G) Soft agar colony formation by U87 MG cells transfected with vector (control) or NK1 3S cDNA (3S plasmid) or control cells treated with NK1 3S protein or
PHA665752 (PHA) at the indicated concentrations.
See also Figure S3.
Cancer Cell
Inhibition of Oncogenic HGF and VEGF Signalingendogenous HGF drives metastatic colonization. B16 cells ex-
pressing luciferase (B16-luc) were used to enable tumor burden
assessment by optical imaging. Metastasis in animals injected
with B16-luc cells expressing NK1 3S was compared with
metastasis in animals injected with empty vector cells and with
metastasis in animals injected with the empty vector cells andthen treated by daily intraperitoneal (i.p.) injection of purified
NK1 3S protein at 50 mg/kg (Figure 5D). Metastatic burden
rose rapidly in the mice receiving empty vector cells (Figure 5D,
circles), whereas mice receiving 3S plasmid bearing cells (Fig-
ure 5D, squares) or control cells and i.p. treatmentwith 3Sprotein
(Figure 5D, triangles) showed few, if any, metastases by studyCancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc. 255
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Figure 5. NK1 3S Inhibits HGF-Driven Tumor Growth, Metastasis,
and Met Kinase Activation In Vivo
(A) Mean tumor volume (± SD) in mice (n = 6/group) implanted with U87 MG
transfectants expressing NK1 WT (squares), NK1 3S (triangles), or empty
vector (circles) at the indicated days postimplantation.
(B) Mean tumor volume (± SD) in mice (n = 6/group) implanted with clonal
SK-LMS-1-derived cell lines expressing NK1WT (squares), NK1 3S (triangles),
or empty vector (circles) at the indicated days postimplantation.
(C) Mean Met activation level (phospho-Met/Met/total protein ± SD; n = 3) in
SK-LMS-1 tumors derived from SK-LMS-1 cells expressing NK1 WT (black),
empty vector (gray), and NK1 3S (unfilled). Asterisks indicate significant
differences from vector control (p < 0.01).
(D) Mean metastatic burden (total photon flux ± SD) over time in mice (n = 10/
group) injected via tail vein with B16-luc cells transfected with empty vector
(circles) or NK1 3S (squares) or injected with empty vector cells and then
treated on day 2 and thereafter with NK1 3S (50 mg/kg) by daily i.p. injection
(triangles).
(E) Meanmetastatic burden (total photon flux ± SD on day 27 postimplantation)
in mice (n = 10/group) implanted subcutaneously with PC3M-luc cells and
treated on day 5 and daily thereafter with NK1 3S protein by i.p. injection at 5 or
25 mg/kg or treated with vehicle alone.
(F) Mean plasma NK1 3S protein concentration (ng/ml, n = 2) in mice (n = 6)
measured at the indicated times following a single i.p. injection of NK1 3S at
50 mg/kg.
See also Figure S4.
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ined ex vivo at study termination for melanin-producing colonies
were consistent with the imaging results (data not shown). The
B16-luc melanoma model was also used for a preliminary
dose-ranging study where mice received i.p. injections of NK1
3S protein at day 2 post-tail vein injection and daily thereafter
for 15 days at 5, 25, and 50 mg/kg (Figure S4). Significant
metastatic suppression was observed at every NK1 3S dose
(p < 0.001).
The antimetastatic efficacy of NK1 3S was also evaluated in
the PC3M spontaneous metastasis model (Figure 5E). The256 Cancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc.PC3M cells used in these studies also expressed luciferase for
metastatic burden assessment. Palpable subcutaneous primary
tumors developedwithin 5 days after cell implantation; mice then
received daily i.p. injections of purified NK1 3S protein at 5 or
25mg/kg, or vehicle alone. Primary tumor growth wasmeasured
at regular intervals using calipers, and metastatic burden was
measured by imaging at study termination. Interestingly, NK1
3S treatment had no significant effect on primary tumor growth
in this model (data not shown); however, a significant and
dose-dependent inhibition of metastasis was observed, with
80% reduction at 25 mg/kg (p < 0.01; Figure 5E).
Analysis of NK1 3S pharmacokinetics in mice (n = 6) showed
that plasma NK1 level peaked between 1 and 3 hr after a
single i.p. injection (50 mg/kg) and declined thereafter (Fig-
ure 5F). Plasma NK1 3S concentration 24 hr postinjection was
150 ng/ml or300-fold over typical murine plasma HGF levels.
Mice treated daily with this dose for 10 days showed no weight
loss, lethargy, or other signs of toxicity. Mice (n = 5) treated on
this dose and schedule, but not implanted with tumor cells,
displayed normal clinical blood chemistry, differential blood
cell count, and hematocrit values; full necropsy analysis of all
tissues and organs showed no signs of toxicity or abnormality
(data not shown).
VEGF165 3S Is a Potent Competitive VEGF Antagonist
To determine whether the strategy used to transform NK1 from
agonist to antagonist could be generalized, we generated
a cDNA encoding opposite charge substitution at the critical
HS binding residues identified by Krilleke et al. (2007) in
VEGF165 (R123E/R124E/R159E or VEGF165 3S). Plasmids
encoding vector alone, VEGF165 WT or VEGF165 3S, were
stably transfected into HEK293 cells that were engineered previ-
ously to express 2.5 3 106 VEGFR2 per cell (293/KDR; Backer
et al., 2005). VEGF165 WT expression in these cells was ex-
pected to result in autocrine KDR activation and transformation,
whereas VEGF165 3S was expected to lack KDR activating
ability and have no effect on phenotype. Ectopic VEGF protein
production by transfectants was measured using a 2-site immu-
noassay with a 1.5 pM detection limit. Marker selected cultures
of WT transfectants produced 1.0 ng/ml/24 hr VEGF165
protein in conditioned media, 3S transfectants produced
2.5 ng/ml/24 hr, and VEGF protein was undetectable in vector
control media (Figure 6A). Like VEGF165 WT, VEGF 3S dimers
and monomers of expected mass were detected under nonre-
ducing and reducing conditions, respectively (Figure 6B). Satu-
ration binding of VEGF165 3S to KDR in vitro (Figure 6C, squares;
KD 19 pM) was equivalent to VEGF165 WT binding (Figure 6C,
circles; KD 23 pM) and consistent with published values
(Ferrara, 2004).
KDR autophosphorylation in each cell line was measured
after 24 hr of serum deprivation (Figure 6D). The basal KDR
phosphorylation level in empty vector transfectants (Figure 6D,
white bar) was similar to that of the parental cell line (not
shown) and 3S transfectants (Figure 6D, dark gray bar). In
contrast, WT transfectant basal KDR phosphorylation level
was 4-fold higher than control or 3S (Figure 6D, light gray
bar; p < 0.001). The KDR autophosphorylation level of the
vector transfectant after 20 min exposure to added VEGF165
protein (2.5 nM) is shown for reference (Figure 6D, black bar).
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Figure 6. VEGF165 3S Dimer Binds KDR
Normally but Does Not Signal
(A) Mean VEGF165 content (ng/mg total cell
protein ± SD; n = 3) in 24 hr conditioned media
prepared from 293/KDR cells transfected with
empty vector (empty), VEGF165 WT (WT), or
VEGF165 3S (3S). Asterisks indicate significant
differences from vector control (p < 0.01).
(B) VEGF165 3S (VEGF 3S; left) and VEGF165
WT (VEGF WT; middle) proteins in 24 hr con-
ditioned media prepared from 293/KDR trans-
fectants and purified recombinant VEGF165
protein (VEGF 4 ng; right) after SDS-PAGE under
nonreducing (NR) and reducing (R) conditions and
immunoblotting with anti-VEGF. Migration of
molecular mass standards (kDa) is indicated by
arrows.
(C) Saturation binding of KDR ectodomain-IgG
fusion protein to VEGF165 WT (squares) or
VEGF165 3S proteins (circles) in vitro. Values are
mean KDR bound (ng/ml ± SD; n = 3).
(D) Mean phospho-KDR level (signal intensity ±
SD; n = 3) in 293/KDR cells transfected with
empty vector (empty; unfilled bar), VEGF165 WT
(WT; light gray bar), VEGF165 3S (3S; dark
gray bar), or empty vector cells treated with
purified VEGF165 WT protein (2.5 nM) for
20 min (+VEGF; black bar). Asterisks indicate
significant differences from empty vector control
(p < 0.01).
(E) Growth rate (mean cell number ± SD; n = 3) of cultured 293/KDR cells transfected with empty vector (circles), VEGF165 WT (squares), or VEGF165 3S
(triangles).
(F) Soft agar colony formation by 239/KDR cells transfected with empty vector, (left), VEGF 3S (middle), or VEGF WT (right).
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Inhibition of Oncogenic HGF and VEGF SignalingConsistent with the levels of KDR activation among the trans-
fectants, significant differences in cell proliferation rate were
observed from day 3 onward: WT transfectants (Figure 6E,
squares) grew significantly faster than the vector control (Fig-
ure 6E, circles) or 3S transfectants (Figure 6E, triangles; p <
0.001 between WT and control or WT and 3S for days 3–5).
These results indicated that WT transfectants, but not 3S trans-
fectants, had acquired autocrine VEGF signaling, even though
3S protein production was twice that of WT. In soft agar colony
formation assays, empty vector and 3S transfectants grew
modestly, if at all (Figure 6F, left and middle panels), whereas
WT transfectants grew robustly (Figure 6F, right panel). All of
these results indicated loss of signaling by VEGF165 3S despite
native KDR binding.
VEGF165 3S also antagonized VEGF165 WT signaling in
intact cells. Concentrated conditioned media harvested from
3S transfectants was added to 293/KDR cells in the presence
of purified VEGF165 WT protein and phospho-KDR levels were
measured (Figures 7A and 7B). Since the conditioned media
could contain other inhibitors of KDR activation, VEGF165 3S
was selectively removed from the media by immunodeple-
tion with anti-VEGF antibody. A mock immunodepletion was
performed in parallel using a nonspecific antibody and the
VEGF165 3S content of the anti-VEGF, and mock-immunode-
pleted media was measured (Figure 7A). VEGF 3S levels in
nonimmunodepleted and mock-immunodepleted media were
similar (1.93 and 1.89 ng/mg total cell protein, respectively; Fig-
ure 7A, white bars), while immunodepletion with anti-VEGF
removed 95% of the 3S protein (0.096 ng/mg total cell protein;Figure 7A, gray bar). VEGF was not detected in media from
empty vector transfectants before or after immunodepletion
(Figure 7A, right). KDR autophosphorylation stimulated by puri-
fied VEGF165 protein (10 ng/ml) in serum-deprived 293/KDR
cells (Figure 7B) was inhibited modestly by VEGF-immunode-
pleted media (Figure 7B, circles), but mock-immunodepleted
media showed significant, dose-dependent inhibition, with
>80% inhibition by media containing 2.5-fold molar excess
VEGF 3S protein (Figure 7B, triangles). In soft agar colony forma-
tion assays, robust growth of 293/KDR cells transfected with
VEGF165 WT (Figure 7C, upper left panel) was inhibited in a
dose-dependent manner by the VEGFR inhibitor pazopanib (Fig-
ure 7C, middle and right upper panels), providing additional
evidence that colony formation was driven by autocrine VEGF/
KDR signaling. VEGF165 3S protein added at 0.06, 0.15, and
0.6 nM also resulted in significant, dose-dependent inhibition
(Figure 7C, lower panels).
Analysis of the spectrum of VEGF 3S antagonism showed
that VEGF165 3S inhibited placenta growth factor (PlGF)-
induced Akt activation (phospho-Akt/total Akt) in EA.hy 926
cells, which express VEGFR1 and R2, with potency similar to pa-
zopanib (Figure 7D). In contrast, VEGF 3S did not block Akt acti-
vation induced by VEGF-D in SCC-25 cells, which express
VEGFR1, R2, and R3 (Figures S5A and S5B). Thus, the pattern
of VEGF 3S inhibition followed the pattern of VEGF-A binding
to VEGFR1 and R2 but not homodimers of VEGFR3, as antici-
pated (Ferrara, 2004).
VEGF165 3S antagonism was independent of NRP1-VEGF-A
protein-protein interaction. NRP1 binds to the VEGF-A HSCancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc. 257
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Figure 7. VEGF165 3S Antagonizes VEGFR Activation, Colony
Formation, and Tumorigenesis
(A) VEGF165 content in media conditioned by 293/KDR cells transfected with
VEGF165 3S (left) or empty plasmid (right), before (‘‘none’’) or after im-
munodepletion by anti-VEGF-A (‘‘a-VEGF’’) or an unrelated control antibody
(‘‘mock’’), expressed as mean ng/mg total protein ± SD (n = 3). Asterisk indi-
cates significant difference from media prior to immunodepletion (p < 0.01).
(B) Phospho-KDR levels (% maximum, ± SD; n = 3) in serum-deprived 293/
KDR cells treated with VEGF165 WT (10 ng/ml) in the presence of concen-
trated conditioned media from 293/KDR VEGF 3S transfectants that were
immunodepleted using a nonspecific control antibody (triangles) or anti-VEGF
(circles). The x axis indicates VEGF165 3S concentration (ng/ml) in conditioned
media before immunodepletion.
(C) Soft agar colony formation by 239/KDR cells expressing VEGF165 WT
(upper left panel), cells treated with the indicated concentrations of pazopanib
(upper middle and right panels), or cells treated with media containing the
indicated concentrations of VEGF165 3S (lower panels).
(D) Dose-dependent inhibition of VEGF- or PlGF-induced Akt activation (mean
% inhibition phospho-Akt/total Akt ± SD) in EA.hy 926 cells. VEGF 3S blocked
Akt activation by VEGF-A (dark blue circles) or PlGF (red squares) with potency
similar to pazopanib (light blue triangles and yellow inverted triangles,
respectively).
(E) Mean tumor volume (mm3 ± SD) in mice (n = 5/group) implanted with 293/
KDR cells (3 3 106 cells per animal) expressing VEGF165 3S (gray inverted
triangles), VEGF165 WT (blue squares), or empty vector (black circles) at the
indicated times postimplantation. Other groups were implanted with a mixture
of empty vector cells and VEGF165 WT transfectants at 1.5 3 106 cells each
(red triangles) or a mixture of VEGF165 WT and VEGF165 3S transfectants at
1.5 3 106 cells each (green diamonds).
See also Figure S5.
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258 Cancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc.binding domain primarily at R165 and secondarily at K147, E152,
and E155 (Parker et al., 2012), i.e., to a surface opposite that of
HS (Figure S5C). Crosslinking studies further showed that
VEGF165 WT and VEGF165 3S bound similarly to NRP1
in vitro (Figure S5D). Functionally, VEGF165 3S antagonized
VEGF signaling similarly in 293/KDR derived cells (Figures 7B,
7C, and 7E), which lack NRP1 (Figure S5E, lanes 4–6), and in
EA.hy 926 cells (Figure 7D), which are NRP1 positive (Figure S5E,
lane 2). The NRP1 present in our experiments was not HS modi-
fied, which is thought to promote NRP1 multimerization and, in
turn, NRP1-VEGFR2 binding and signaling (Shintani et al.,
2006). Like NK1, we found that heparin promoted clustering of
VEGF165 WT, but not of VEGF165 3S (Figure S5F). Thus, if
HS-modified NRP1 enhances VEGF signaling in part by
promoting VEGF clustering, VEGF165 3S would be expected
to antagonize that process.
VEGF 3S Inhibits VEGF-Driven Tumor Growth
and Angiogenesis In Vivo
To test whether VEGF165 3S protein could antagonize KDR-
driven tumorigenicity in mice, animals were implanted subcuta-
neously with VEGF165 WT transfected 293/KDR cells (3 3 106
per animal), with the same number of VEGF165 3S transfected
cells or with a suspension containing 1.5 3 106 cells of each
line. Additional control groups received the empty vector 293/
KDR cells (3 3 106 per animal) or the empty vector cells
combined with VEGF WT transfectants at 1.5 3 106 cells each.
The latter group indicated the growth rate of tumors arising
from 1.5 3 106 VEGF WT transfectants in the presence of
‘‘neutral’’ cells providing the same initial mass; a growth rate
below this threshold in the group implanted with VEGF WT +
VEGF 3S transfectants could be attributed to inhibition of
VEGF WT-driven tumor growth by VEGF165 3S. Indeed, VEGF
WT transfected 293/KDR cells formed tumors fastest (Figure 7D,
blue squares), whereas VEGF 3S transfectants did not form
tumors prior to study termination (Figure 7D, gray inverted trian-
gles), and animals implantedwith theWT+3Scell mix (Figure 7D,
green diamonds) formed tumors at a significantly lower rate than
the control WT + empty vector group (Figure 7D, red triangles)
throughout the study (p < 0.05).
Tumorigenesis by the parental cell line, despite its inability to
grow in soft agar, indicated that it was driven by host VEGF.
This conclusion is supported by prior work where the generation
of knockin mice expressing a humanized form of VEGF-A was
needed to overcome incomplete suppression of human tumor
xenograft growth by antihuman VEGF-A antibodies that did not
block murine VEGF activity (Gerber et al., 2007). Therefore, the
failure of the 3S transfectants to form tumors indicates VEGF
3S antagonism of tumorigenesis driven by murine VEGF. More-
over, significant inhibition of tumor growth by VEGF165 3S in
animals receiving the WT + 3S transfectant cell mix indicates
antagonism of the combined impact of paracrine murine VEGF
and autocrine human VEGF.
Tumor angiogenesis was also significantly blocked in mice
receiving VEGF 3S transfected cells (Figure 8). Immunohistoche-
misty using anti-CD34 showed that the extent of tumor vascular-
ization, from highest to lowest, was 293/KDR/WT VEGF trans-
fectants alone (Figure 8A), 293/KDR/WT VEGF cells + vector
transfected 293/KDR cells mixed 1:1 (Figure 8B), vector
500 m 500 m500 m500 m
200 m200 m 200 m 200 m
A B DC
Figure 8. VEGF165 3S Antagonizes VEGF-Driven Tumor Angiogenesis
Murine CD34 immunohistochemical analysis (low magnification above, higher magnification below) of tumors from animal groups as described in Figure 7.
(A) 293/KDR/VEGF WT cell tumors; (B) 293/KDR/VEGF WT + control 293/KDR cell (1:1) tumors; (C) control 293/KDR cell tumors; (D) 293/KDR/VEGF WT + 293/
KDR/VEGF 3S cell (1:1) tumors.
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Inhibition of Oncogenic HGF and VEGF Signalingtransfectants alone (Figure 8C), and 293/KDR/WT VEGF + 293/
KDR/3S VEGF transfectants mixed 1:1 (Figure 8D). This pattern
is consistent with tumor angiogenesis driven by both autocrine
human and paracrine murine VEGF (Figures 8A and 8B) relative
to tumor angiogenesis driven by murine VEGF alone (Figure 8C)
and with substantial inhibition of tumor angiogenesis by VEGF
3S (Figure 8D).
Histopathology analysis indicated that the tumors formed by
293/KDR cell transfectants (vector, VEGF WT, VEGF WT +
vector, VEGF WT + VEGF 3S) were uniformly carcinoma. Full
necropsy analysis of all tissue and organs showed no signs of
toxicity or damage in any tissue from mice implanted with 293/
KDR transfectants.
DISCUSSION
Our work builds on several prior studies showing that HS-HGF
interaction is critical for HGF signaling (Hartmann et al., 1998;
Lietha et al., 2001; Sakata et al., 1997; Schwall et al., 1996; Zion-
check et al., 1995). The loss of biological activity by combinedsubstitution of K60, K62, and R73 with acidic residues identifies
this surface region as essential for NK1 biological signaling and
implies that HS binding at secondary sites is insufficient for
NK1 signaling. The partial loss of activity associated with substi-
tutions at 73 and 60/62 suggests that each contribute to HS
interactions at this site. Our results further indicate that
HS-NK1 interactions promote receptor activation and signaling
by enhancing NK1-Met interaction and by stabilizing NK1 multi-
mers, which may in turn facilitate receptor clustering, kinase
activation, and effector recruitment (Gherardi et al., 2006; Hart-
mann et al., 1998; Lietha et al., 2001; Sakata et al., 1997; Schwall
et al., 1996; Tolbert et al., 2010).
We believe that three critical features define the mechanism of
HGF inhibition by NK1 3S: (1) retention of optimal N domain-Met
binding through negative charge substitutions in NK1 3S that
mimic occupancy of the primary HS binding site; a prior report
provides structural evidence to this effect (Tolbert et al., 2010),
(2) repulsion of HS from the ligand-receptor complex by the
negative charge substitutions, and (3) competitive displacement
of HGF fromMet by the native K1 domain of NK1 3S.We proposeCancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc. 259
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Inhibition of Oncogenic HGF and VEGF Signalingthat occupancy of the primary ligand binding site in Met without
HS support of ligand-Met complex clustering and associated
conformational changes results in a signaling blockade.
In addition to its value as a research tool, NK1 3S may have
therapeutic potential. The critical role of HGF-Met signaling in
a variety of human cancers has made Met an important anti-
cancer drug target. Met blockade has been achieved using
ATP binding site antagonists, neutralizing antibodies, decoy
receptors, single-chain HGF derivatives (Cecchi et al., 2010),
synthetic HS mimetics (Fuster and Esko, 2005), and engineered
NK1 forms affecting the dimerization interface in K1 (Tolbert
et al., 2010; Youles et al., 2008). Like the latter, NK1 3S blocks
signaling by disrupting ligand dimer/multimer formation, but
unlike those mutants it does so by blocking HS facilitation of
that process. Each of these approaches has advantages as
well as limitations. Our choice to develop NK1 instead of full-
length HGF is based on the complexity of HGF protein and the
technical obstacles this imposes on its manufacture. The chal-
lenges of administering large HGF-derived antagonists, such
as NK4 and uncleavable pro-HGF, have been met by using viral
vectors or naked DNA plasmids (Cecchi et al., 2010). These
methods can provide sustained delivery but do not allow the
level of control inherent in administering the encoded proteins.
NK1 can be expressed in P. pastoris at yields high enough
(>1 g/l) to be commercially tractable. Our results support the
efficacy of systemically delivered NK1 3S protein as an antitumor
and antimetastatic agent as well as its practicality as an alterna-
tive to larger HGF-derived antagonists.
Wefind that VEGF1653SbindsKDR-likeVEGF165WTprotein,
fails to induceKDRkinase activity, andantagonizesVEGF165WT
binding and signaling in vitro and in vivo. A critical distinction
between VEGF165 3S and alanine substitutions made at these
positions (Krilleke et al., 2007), or the VEGF isoform VEGF121,
is that the opposite charge substitutions in VEGF3Sare designed
to repel HS and thereby disrupt both ligand-HS and weaker
receptor-HS interactions. The striking parallels in antagonism
by 3S forms of NK1 and VEGF165 strengthen our assertion of
a common role for HS in receptor activation and show that tar-
geted disruption of critical HS binding sites is an antagonist
development strategy that can be extended to other HS-binding
growth factors. Consistent with findings for NK1, VEGF-HS inter-
action occurs through sulfated HS side-chains and three key
VEGF residues, with secondary contributions from one or two
others (Krilleke et al., 2007). The analogous roles of HS in NK1/
Met and VEGF165/KDR signaling, in the absence of underlying
structural similarity, suggests that this occurs through conver-
gent evolution. Thus, any similarity in the spatial arrangement of
the primary HS binding site surfaces themselves would be driven
by adaptation to the commonbinding partner, HS, as opposed to
a common ancestral protein sequence or structure.
The present understanding of KDR activation by VEGF165
and HS suggests a mechanistic basis for signaling antagonism
by the targeted disruption of HS-ligand binding. The VEGF
binding site in KDR encompasses IgG-like domains (D) 1–3: D2
contains primary contacts, and D1 and D3 contribute to overall
binding affinity and specificity (Christinger et al., 2004; Fuh
et al., 1998). Consistent with findings presented here for NK1,
HS was found to be required for high-affinity binding of
VEGF165 to KDR ectopically expressed in HS-negative CHO260 Cancer Cell 22, 250–262, August 14, 2012 ª2012 Elsevier Inc.745 cells (Dougher et al., 1997). Similar to Met (Rubin et al.,
2001) and FGF receptors (Mohammadi et al., 2005), KDR also
interacts directly with HS through at least one site located
between D6 and D7 (Dougher et al., 1997). Recent structural
studies of KIT, PDGFR, and VEGFR highlight the importance of
homotypic receptor-receptor interaction domains in stabilizing
receptor dimerization and kinase transactivation: direct contacts
between D4 domains for KIT and D7 domains for KDR are
enabled by ligand-induced conformational changes in the
receptor ectodomain (Lemmon and Schlessinger, 2010; Tao
et al., 2001; Yang et al., 2010). In these models, sequential
binding events promote and incrementally stabilize HS-ligand-
receptor aggregates capable of signaling. We hypothesize that
VEGF165 first binds KDR D2; the weaker VEGF165 D1 and
VEGF165D3 interactionsmay be stabilized byHS-VEGF interac-
tion and by HS-VEGF-KDR bridging at D6/D7. For VEGF165 3S,
receptor binding at D2 should occur, but subsequent weaker
interactions normally stabilized by HS and induced changes in
receptor conformation could fail. VEGF-HS interactions may
also induce conformational changes that enable the apposition
of KDR D7 domains (Wijelath et al., 2010) and, in turn, homotypic
interaction and kinase transactivation; VEGF165 3S is likely to
disrupt such events. The role of NRP1 in VEGF signaling is
complex, involving protein-protein interactions and protein-HS
interactions when NRP1 is HS modified (Shintani et al., 2006).
VEGF165 3S engages NRP1 via the former, but would be
expected to disrupt the latter. Collectively, our observations
underscore the importance of specific HS interactions in facili-
tating events after ligand binding, which are required for KDR
activation, and expose their susceptibility to targeted disruption.
HS binding growth factors promote tumor growth, angiogen-
esis, and metastasis in a variety of human cancers. In addition
to the strategy described here, oligosaccharide HS mimetics
and modified heparin fragments can act as HS binding antago-
nists (Fuster and Esko, 2005). However, the complexity of HS
GAGs challenges the development of potent and selective
agents, and frequent alterations in HS GAG composition in
tumors (Fuster and Esko, 2005) may render such agents less
competitive for ligand binding. In contrast, opposite substitu-
tions to critical HS binding residues in an otherwise wild-type
protein ligand are simple to introduce, unaffected by tumor HS
GAG composition, and inherently pathway selective. These
features suggest that it may be an expedient and practical route
for the development of antagonists of HS binding growth factors.
EXPERIMENTAL PROCEDURES
Reagents and Cell Culture
See Supplemental Information.
Plasmids for NK1 andVEGF165, Protein Expression, andPurification
NK1 proteins were produced in E. coli as described (Stahl et al., 1997). Plas-
mids for expression of NK1 3S, NK1 WT, VEGF165 WT, and VEGF165 3S
under cytomegalovirus promoters possess their native signal peptide
sequences and G418 resistance. Plasmids for P. pastoris expression of NK1
proteins were generated and protein purified as described in Supplemental
Information.
NMR Structural Analysis
Isotope-labeled proteins were expressed E. coli in minimal media containing
either 15NH4Cl or both
15NH4Cl and
13C-labeled glucose. Triple-labeled
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Inhibition of Oncogenic HGF and VEGF Signalingproteins (15N/13C/2H) were prepared similarly, except the media contained
98% D2O.
1H-15N correlation spectra for substituted and WT NK1 proteins
were collected as described (Zhou et al., 1999). NK1 backbone resonance
assignments were made using 15N/13C/2H-NK1 and standard triple resonance
experiments.
Immunoassays and Binding Assays
Met, KDR, HGF, and VEGF content in cell lysates, tissue extracts, and condi-
tioned media was determined using 2-site immunoassays developed for use
with the Meso Scale Discovery (MSD) SectorImager 2400 plate reader; HGF
and Met assays are described in Supplemental Information; other assays
were fromMSD.Met and KDR activation in cell lysates or tumor tissue extracts
included parallel detection with antireceptor antibodies and specific antiphos-
pho-receptor antibodies or 4G10 (Millipore).
Binding assays were also performed on the MSD platform. NK1 saturation
binding to immobilized Met ectodomain-IgG fusion protein was measured
using Ru taggedWT or 3S ligand. Displacement experiments includedmultiple
untagged ligand concentrations in the presence of Ru tagged ligand. NK1-HS
saturation binding to immobilized heparin-biotin was measured using Ru
tagged NK1 WT or 3S proteins. KDR-Ig ectodomain saturation binding to
immobilized VEGF165 WT or 3S was measured using Ru tagged anti-KDR.
All measurements were made on triplicate samples. GraphPad Prism v5.0
was used for all statistical analyses. Additional details are included in Supple-
mental Information.
Cell Motility, Mitogenesis, and Colony Formation Assays
Cell motility in modified Boyden chambers and DNA synthesis by [3H]thymi-
dine incorporation were measured as described (Rubin et al., 2001). MDCK
cell scatter was assessed as described (Stahl et al., 1997). U87 MG or 293/
KDR derived cell line proliferation in quadruplicate wells of 6-well plates was
measured by counting in a Cellometer (Nexcelom Bioscience). Assays for
colony formation in soft agar were performed as described (Castagnino
et al., 2000). Differences betweenmean values were determined by t test using
GraphPad Prism v5.0.
Tumorigenesis, Metastasis, and Pharmacokinetic Assays
Experiments with SCID/beige mice were performed in accordance with
National Institutes of Health (NIH) Guidelines for Care and Use of Laboratory
Animals using protocols approved by the Institutional Animal Care and Use
Committee of the Center for Cancer Research, National Cancer Institute.
Details for all animal studies are included in Supplemental Information. Briefly,
U87 MG, SK-LMS-1, or 293/KDR derived cell lines were injected subcutane-
ously into mice, and tumor volumes were calculated from caliper measure-
ments. 293/KDR cell derived tumors were harvested at study termination for
histopathology and immunohistochemical analysis of murine CD34 protein
localization. B16-luc derived cells for induced metastasis studies were
injected through the tail vein; in some studies, mice also received daily i.p.
injections of purified NK1 3S (or vehicle) at doses indicated in the text. For
spontaneous metastasis studies, PC3M-luc cells were implanted subcutane-
ously, and mice were treated by i.p. injection of vehicle or NK1 3S starting on
day 5. Metastatic burden was determined by luciferase imaging. Plasma NK1
3S levels were measured in mice after a single i.p. injection of NK1 3S at the
indicated times postinjection. NK1 protein was analyzed by SDS-PAGE and
immunoblotting. Statistical analysis, curve fitting, and IC50 determinations
were performed using GraphPad Prism v5.0.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, five figures, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.06.029.
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